Lantern | --- | --- | |-------|-------| | | | | | | | | | May 3, 2021 4:30 PM Eastern https://ir.lanternpharma.com/ LTRN FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of ...

Financial Data and Key Metrics Changes - For Q1 2021, the company reported a net loss of approximately $2.45 million or $0.24 per share, compared to a net loss of approximately $477,000 or $0.24 per share for Q1 2020 [51] - Research and development expenses increased to approximately $1.3 million in Q1 2021 from $137,000 in Q1 2020, primarily due to increased research studies and team expansion [52] - General and administrative expenses rose to approximately $1.2 million in Q1 2021 from approximately $340,000 in Q1 2020, attributed to costs associated with operating as a public company [53] - The cash position as of March 31, 2021, was $81.4 million, bolstered by a $69 million follow-on public offering in January, extending the cash runway through mid-2025 [56] Business Line Data and Key Metrics Changes - The RADR AI platform surpassed 4.6 billion data points by the end of April 2021, representing a 16-fold increase since May 2020 and nearly four-fold growth since the beginning of 2021 [11][17] - The company initiated pre-clinical development of LP-284, a new molecule targeting hematologic cancers, which has shown exceptional sensitivity [12] Market Data and Key Metrics Changes - The LP-300 drug candidate targets a growing but unaddressed type of non-small cell lung cancer among non-smokers, which accounts for approximately 20% of new non-small cell lung cancer cases globally, with an estimated annual spending of $2.5 billion on therapies for this patient population [29] Company Strategy and Development Direction - The company aims to leverage its RADR AI platform to transform oncology drug development by reducing the pace, cost, and risk associated with bringing therapies to market [9][23] - The collaboration with Actuate Therapeutics is expected to enhance the development of their drug candidate using the RADR platform, potentially generating novel intellectual property [21][22] - The company is focused on expanding its pipeline of oncology drug candidates, including the development of an antibody drug conjugate program expected to enter clinical trials in 2022 [65] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering a new era of drug discovery, emphasizing the importance of AI and data-driven approaches in accelerating drug development [24][66] - The company anticipates significant opportunities for R&D collaborations and aims to establish itself as a leader in AI-driven oncology drug discovery [68][69] Other Important Information - The company has filed over 10 patent applications to strengthen its intellectual property portfolio, covering various aspects of its RADR platform and drug candidates [13] - The company has a disciplined approach to acquiring new drug assets, utilizing an internal database to evaluate oncology trials and prioritize potential candidates [94][95] Q&A Session Summary Question: What is behind the exponential growth of data points? - The growth is attributed to team expansion, improved resources, and a focus on automation to enhance data collection and management [75][76] Question: Can you clarify the relationship between LP-184 and LP-284? - LP-284 is a stereoisomer of LP-184, with distinct properties and potential effectiveness in hematologic cancers [78][79] Question: What is the cash position and appetite for acquisitions? - The company has $81.4 million in cash, with plans to grow R&D expenses while remaining open to acquiring new candidates [91][92] Question: Can you provide details on the LP-300 trial and potential partnerships? - The LP-300 trial will focus on never smoker lung adenocarcinoma patients, with plans to explore partnerships with larger pharmaceutical companies as the trial progresses [99][101] Question: Will there be cash milestones or royalty payments from collaborations? - The company plans to focus on developing high-value oncology therapies with partners, potentially involving equity or deferred cash based on success [113][115]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Employer | | of Incorporation) | File Number) | Identification No.) | | 1920 McKinney Avenue, 7th Floor | | | Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Mar ...

| --- | --- | --- | |-------------------------------------------------------------------------|-------|-------| | Lantern Pharma Company Overview April 6, 2021 | | | | Leveraging A.I., Machine Learning & Genomics to Rescue, Reposition and | | | | Develop Targeted Cancer Therapies | | | FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. ...

Financial Data and Key Metrics Changes - For Q4 2020, the company reported a net loss of $2.9 million, or $0.47 per share, compared to a net loss of $675,000, or $0.34 per share, for Q4 2019 [58] - For the full year 2020, the net loss was $5.9 million, or $1.37 per share, compared to a net loss of $2.4 million, or $1.23 per share, for 2019 [61] - Research and development expenses increased by 135% from $953,000 in 2019 to $2.2 million in 2020 [62] - General and administrative expenses rose by 149% from $1.5 million in 2019 to $3.7 million in 2020 [63] - As of December 31, 2020, the company had working capital of approximately $19.7 million, primarily due to the net proceeds from its IPO [61] Business Line Data and Key Metrics Changes - The company has increased the number of active development programs from three to seven since its IPO in June 2020 [27][18] - The RADR AI platform surpassed 1.1 billion data points by the end of 2020, with plans to reach 3 billion in 2021 [14] Market Data and Key Metrics Changes - The global antibody-drug conjugate (ADC) cancer therapy market is expected to exceed $10 billion by 2026 and $15 billion by 2030 [52] Company Strategy and Development Direction - The company aims to leverage its RADR AI platform to accelerate drug development and reduce costs associated with oncology therapies [22][72] - The focus is on building a portfolio of high-value oncology drug candidates that can be partnered for pivotal registration trials or licensed out [72] - The company is pursuing partnerships with biopharma companies to enhance the development of their programs using the RADR platform [17] Management's Comments on Operating Environment and Future Outlook - Management believes that the current era represents a "golden age" of artificial intelligence in drug development, which will significantly impact the industry [21][73] - The company is confident that its AI-driven approach can save millions in drug development costs while accelerating the path to commercialization [33] Other Important Information - The company closed a $69 million follow-on public offering in January 2021, extending its cash runway through mid-2025 [65] - The company has initiated collaborations with leading cancer research institutions, including Johns Hopkins and Georgetown University, to advance its drug candidates [28][38] Q&A Session Summary Question: How should the quarterly burn be viewed with recent updates on the ADC program and ATRT? - Management indicated that the quarterly burn will increase substantially as they move towards launching LP-300 and starting additional clinical trials for LP-184 and the ADC program [81][82] Question: Regarding the ATRT opportunity, how will pricing offset the small patient population? - Management emphasized the importance of benefiting the patient population initially, with plans to expand the drug's use to other similar tumors once it is on the market [84][86] Question: Can you provide insights into the ADC program and its timing? - Management confirmed progress in identifying antibody targets and plans to provide a broader update later in the year [92] Question: Can you elaborate on the recent BMC Bioinformatics paper and its implications for the RADR platform? - Management highlighted that the paper validates the RADR platform's ability to make decisions about drug indications and genomic information [96][98] Question: Is there potential for the ATRT indication to qualify for a priority review voucher? - Management believes there is potential for ATRT to qualify for the priority review voucher program, which could add significant value [103]

Part I [Business](index=6&type=section&id=Item%201.%20Business) Lantern Pharma uses its RADR® A.I. platform to streamline oncology drug development by identifying patient-specific genomic signatures - The company's core strategy is to leverage its **A.I. platform, RADR®**, to rescue and develop small molecule oncology drugs by identifying patient populations with specific **genomic biomarkers** that predict a positive response[17](index=17&type=chunk)[18](index=18&type=chunk) - The **RADR® platform** integrates over **1.2 billion data points**, using machine learning to uncover genomic signatures correlated to drug response, aiming to de-risk and accelerate the clinical trial process[17](index=17&type=chunk)[19](index=19&type=chunk) Drug Candidate Pipeline Overview | Drug Candidate | Generic Name | Development Stage | Target Indication(s) | | :--- | :--- | :--- | :--- | | **LP-100** | Irofulven | Phase II (Out-licensed to Allarity) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | | **LP-300** | Tavocept | Planning Phase II | Non-Small Cell Lung Cancer (NSCLC) in never-smokers | | **LP-184** | Hydroxyureamethylacylfulvene | Preclinical | Solid tumors (Prostate, Pancreatic, Ovarian), Glioblastoma | | **ADC Program** | LP-184 based | Research Optimization | Select Solid Tumors | [Our Drug Candidate Pipeline](index=11&type=section&id=Our%20Drug%20Candidate%20Pipeline) The company's pipeline includes LP-100 (out-licensed), LP-300 (Phase II prep), and preclinical LP-184, plus new ADC and CNS programs - The company is building its pipeline by in-licensing clinical-stage drug candidates that were previously discontinued and using its **RADR® platform** to identify patient subgroups for targeted development[41](index=41&type=chunk) - An **antibody drug conjugate (ADC) program** was initiated in early 2021, leveraging the **LP-184 molecule** for select solid tumors, supported by an Evaluation Agreement with Califia Pharma, Inc[22](index=22&type=chunk)[48](index=48&type=chunk)[49](index=49&type=chunk) - The company is increasing its focus on **Central Nervous System (CNS) cancers**, including Glioblastoma (GBM) and Atypical Teratoid Rhabdoid Tumor (ATRT), based on promising preclinical data showing **LP-184** can cross the blood-brain barrier[50](index=50&type=chunk)[51](index=51&type=chunk) [Our RADR Platform](index=13&type=section&id=Our%20RADR%20Platform) The proprietary RADR® A.I. platform analyzes over 1.2 billion oncology data points to identify predictive biomarkers with high accuracy - The **RADR® platform** has analyzed over **1.2 billion oncology-specific data points** from more than 140 drug-cancer interactions and 55,000 patient records to enhance its predictive power[68](index=68&type=chunk) - The platform's workflow reduces approximately 18,000 genetic features to a targeted set of **less than 50 candidate biomarkers** predictive of a patient's response to a specific drug molecule[66](index=66&type=chunk) - Validation studies demonstrated high accuracy, with external retrospective analysis of 10 clinical studies achieving **over 80% response prediction accuracy**, and internal analysis of 120 drug-tumor interactions achieving **over 85% accuracy**[68](index=68&type=chunk) [Our Strategy](index=19&type=section&id=Our%20Strategy) The company's strategy focuses on advancing its pipeline, expanding through drug rescue, and enhancing the RADR® platform data - Key growth strategies include advancing **LP-184** and **LP-300**, expanding the pipeline by rescuing other failed drug candidates, and identifying novel combination therapies using the **RADR® platform**[73](index=73&type=chunk) - The company plans to increase the number of data points in its RADR® A.I. platform from over **1.2 billion to approximately three billion** by the end of 2021[73](index=73&type=chunk) - A core objective is to continue developing and patenting **intellectual property** related to precision therapies, patient stratification, and genomic/biomarker signatures[76](index=76&type=chunk) [Intellectual Property](index=54&type=section&id=Intellectual%20Property) The company protects drug candidates with over 70 patents and its RADR® A.I. platform via trade secrets and confidentiality agreements - As of March 2021, the company owns or controls over **70 active patents** and patent applications across **14 patent families**[40](index=40&type=chunk)[208](index=208&type=chunk) Patent Portfolio Expiration Outlook | Drug Candidate | Patent Expiration Range | | :--- | :--- | | **LP-100** | Patents expire in August 2026 | | **LP-184** | Patents expire in August 2026; new applications could extend to May 2040 | | **LP-300** | Patents expire in March 2028; new applications could extend to March 2040 | - The **RADR® platform** is protected by **trade secrets** and **confidentiality agreements**, focusing on proprietary A.I. methodologies, data curation, and algorithmic models of biological processes[213](index=213&type=chunk)[215](index=215&type=chunk) [Competition](index=57&type=section&id=Competition) The company faces intense competition from major pharmaceutical and biotech firms, and A.I. drug development companies - The company faces competition from major pharmaceutical and biotech companies that have significantly **greater financial resources** and expertise in R&D, manufacturing, and marketing[226](index=226&type=chunk) - In the A.I.-driven drug development space, competitors include **AI Therapeutics, Atomwise, and Benevolent AI** for drug discovery, and **Adaptive Biotechnologies and Concerto HealthAI** for biomarker development[229](index=229&type=chunk) - For its prostate cancer programs (**LP-100, LP-184**), key competitors include approved drugs like Astellas/Pfizer's **Xtandi** and Johnson & Johnson's **Zytiga**[231](index=231&type=chunk) [Government Regulation](index=58&type=section&id=Government%20Regulation) The company's drug development is subject to extensive FDA regulation, requiring rigorous approval processes and compliance with various healthcare laws - Drug candidates must undergo a rigorous approval process with the **FDA**, starting with an **IND application** for clinical trials and culminating in an **NDA submission** for marketing approval[236](index=236&type=chunk)[237](index=237&type=chunk) - The FDA's **Orphan Drug Act** provides incentives for developing drugs for rare diseases (affecting **fewer than 200,000 people** in the U.S.), including **seven years of market exclusivity** upon approval[251](index=251&type=chunk)[253](index=253&type=chunk) - Post-approval, the company is subject to **ongoing FDA regulation**, including monitoring, adverse event reporting, and restrictions on off-label promotion, with non-compliance potentially leading to fines, recalls, or approval withdrawal[259](index=259&type=chunk)[262](index=262&type=chunk) [Risk Factors](index=70&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks including limited operating history, net losses, funding needs, drug development failures, and reliance on third parties - The company has a limited operating history, has never generated revenue from drug sales, and incurred significant operating losses of **$5.9 million in 2020**, with continued losses expected[295](index=295&type=chunk)[297](index=297&type=chunk) - **Substantial additional funding** will be required to advance clinical trials and operations, and failure to raise capital could force delays, reductions, or elimination of drug development programs[302](index=302&type=chunk) - The company's **'drug rescue' strategy** for candidates that previously failed clinical trials involves unique risks, such as shorter patent terms and potential skepticism from partners and regulators[316](index=316&type=chunk)[318](index=318&type=chunk) - The business is highly dependent on **third parties** for conducting clinical trials (CROs) and manufacturing drug supplies, and any failure by these parties could substantially harm development programs[405](index=405&type=chunk)[410](index=410&type=chunk) [Properties](index=117&type=section&id=Item%202.%20Properties) The company's Dallas office is under a month-to-month lease, with reduced commitment due to remote work during the COVID-19 pandemic - The principal executive office is in **Dallas, Texas**, under a **month-to-month lease**, with the lease commitment **significantly reduced** in August 2020 due to remote work during the COVID-19 pandemic[495](index=495&type=chunk) [Legal Proceedings](index=117&type=section&id=Item%203.%20Legal%20Proceedings) The company is not currently a party to any legal proceedings and is unaware of any pending or threatened litigation that could materially affect its business - The company is **not currently a party** to any legal proceedings and is unaware of any pending or threatened litigation that could have a material adverse effect on its business[496](index=496&type=chunk) Part II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=118&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's common stock began trading on Nasdaq in June 2020, has never paid dividends, and used **$4.57 million** of IPO proceeds by year-end 2020 - The company's common stock began trading on the **Nasdaq Capital Market** under the symbol "**LTRN**" on **June 11, 2020**[500](index=500&type=chunk) - The company has **never paid cash dividends** and does not plan to in the foreseeable future, retaining all funds for business development[502](index=502&type=chunk) - From the June 2020 IPO, which raised net proceeds of **$23.4 million**, approximately **$4.57 million** was used by December 31, 2020, for drug development, the RADR® platform, and general corporate purposes[509](index=509&type=chunk)[510](index=510&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=120&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) The company reported a **$5.9 million** net loss in 2020, driven by increased G&A and R&D expenses, with liquidity boosted by its 2020 IPO and 2021 offering Financial Performance Summary (2020 vs. 2019) | Metric | 2020 ($) | 2019 ($) | Change (%) | | :--- | :--- | :--- | :--- | | **Revenue** | $0 | $0 | N/A | | **General & Administrative Expenses** | $3,664,965 | $1,475,000 | +149% | | **Research & Development Expenses** | $2,243,225 | $953,185 | +135% | | **Net Loss** | $(5,908,190) | $(2,428,185) | +143% | - The increase in G&A expenses was primarily due to higher corporate insurance (**$1.08 million**), stock compensation (**$604 thousand**), and labor costs (**$512 thousand**)[531](index=531&type=chunk) - The rise in R&D expenses was driven by increased labor (**$489 thousand**), stock compensation (**$470 thousand**), and research study costs (**$194 thousand**)[532](index=532&type=chunk) - The company's cash position increased significantly from **$1.2 million** at year-end 2019 to **$19.2 million** at year-end 2020, mainly due to the IPO, with a subsequent offering in January 2021 raising an additional **$69 million** in gross proceeds[538](index=538&type=chunk) [Financial Statements and Supplementary Data](index=131&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) Audited financial statements show a **$5.9 million** net loss in 2020, with **$19.2 million** cash and **$20.4 million** total assets as of year-end 2020 Consolidated Balance Sheet Highlights (As of Dec 31, 2020) | Account | Amount ($) | | :--- | :--- | | **Assets** | | | Cash | $19,229,232 | | Total Current Assets | $20,236,922 | | **Total Assets** | **$20,359,634** | | **Liabilities & Equity** | | | Total Current Liabilities | $552,339 | | **Total Liabilities** | **$660,839** | | **Total Stockholders' Equity** | **$19,698,795** | Consolidated Statement of Operations Highlights (Year Ended Dec 31, 2020) | Account | Amount ($) | | :--- | :--- | | General and administrative | $3,664,965 | | Research and development | $2,243,225 | | **Total operating expenses** | **$5,908,190** | | **Net Loss** | **$(5,908,190)** | - As of December 31, 2020, the company had federal net operating loss (NOL) carryforwards of approximately **$11.5 million** to offset future taxable income, with a full valuation allowance recorded against deferred tax assets due to a history of losses[685](index=685&type=chunk) [Controls and Procedures](index=152&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded disclosure controls were effective as of December 31, 2020, having remediated prior material weaknesses in internal controls - Management concluded that the company's disclosure controls and procedures were **effective** as of December 31, 2020[692](index=692&type=chunk) - Material weaknesses in internal controls identified prior to the IPO (related to financial closing processes and oversight) were **remediated** during 2020 through hiring a CFO, adding resources, and implementing new procedures[690](index=690&type=chunk)[691](index=691&type=chunk) - As an emerging growth company, a formal management report on internal control over financial reporting is **not required** until the Annual Report for the fiscal year ending December 31, 2021[693](index=693&type=chunk) Part III [Directors, Executive Officers, Corporate Governance, Compensation, and Security Ownership](index=153&type=section&id=Items%2010-14) Information for Items 10-14, covering governance, compensation, and ownership, is incorporated by reference from the forthcoming 2021 proxy statement - Information regarding directors, executive officers, corporate governance, executive compensation, security ownership, related party transactions, and principal accountant fees is **incorporated by reference** from the forthcoming 2021 proxy statement[697](index=697&type=chunk)[698](index=698&type=chunk)[699](index=699&type=chunk) Part IV [Exhibit and Financial Statement Schedules](index=154&type=section&id=Item%2015.%20Exhibit%20and%20Financial%20Statement%20Schedules) This section lists all financial statements and exhibits filed with the Form 10-K, including corporate governance documents and material contracts - This section contains the list of **financial statements and exhibits** filed with the annual report, with all financial statement schedules omitted as the information is included in the financial statements or notes[704](index=704&type=chunk)[705](index=705&type=chunk) - Exhibits include the company's certificate of incorporation, by-laws, **material contracts** such as the Technology License Agreement with AF Chemicals and the Drug License and Development Agreement with Allarity Therapeutics, and executive employment agreements[706](index=706&type=chunk)

Financial Data and Key Metrics Changes - As of September 30, 2020, the company reported working capital of approximately $21.7 million, primarily driven by the net proceeds of its IPO that closed on June 15, 2020 [30] - For Q3 2020, the company reported a net loss of $1.7 million compared to a net loss of $669,652 in Q3 2019 [31] - General and administrative expenses increased by 149% to $1,100,719 from $441,251 in Q3 2019, primarily due to increases in labor, business development, and corporate insurance expenses [31] - Research and development expenses increased by 163% to $600,769 from $228,401 in Q3 2019, driven by higher research study expenses and employee-related costs [32] - The company had nine full-time employees, two part-time employees, and four consultants as of the end of the quarter [33] Business Line Data and Key Metrics Changes - The company achieved a significant milestone by surpassing 1.1 billion data points in its RADR AI platform, with expectations to reach 3 billion by the end of 2021 [11][12] - The RADR platform's growing datasets are essential for streamlining drug development and identifying mechanisms driving drug activity and patient types that will benefit from targeted therapies [14] Market Data and Key Metrics Changes - The company entered into collaborations with Fox Chase Cancer Center for pancreatic cancer and Georgetown University for prostate cancer, focusing on the development of LP-184 [18][21] - The collaborations aim to develop robust gene signatures for clinical trials, potentially providing personalized therapy options for patients [21] Company Strategy and Development Direction - The company aims to establish itself as a leading AI-driven drug discovery and development franchise focused on oncology, leveraging large-scale data analytics to uncover new opportunities and enhance drug development efficiency [39][40] - The strategy includes rescuing previously deprioritized therapeutic candidates and developing new biomarker-guided drug candidates, with a goal of adding one new program every 12 to 18 months [40][26] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of the growing RADR platform and its potential to drive insights and accelerate drug development, particularly in the context of the ongoing advancements in AI and data analytics [15][41] - The company is focused on achieving existing milestones and advancing its programs into clinical trials to make a meaningful impact on cancer patients [40] Other Important Information - The company plans to continue building a portfolio of high-value small molecule oncology drug candidates and is focused on partnerships with larger biotech and pharmaceutical companies for pivotal registration-directed trials [38][41] Q&A Session Summary Question: How should we think about the incremental benefit of additional data points when you're already over 1 billion? - Management indicated that more data points enhance the precision of drug response signatures and allow for better understanding of tumor biology, which can lead to significant cost savings in drug development [46][47][48] Question: How should we think about the burn rate going forward and potential headcount changes? - Management expects R&D expenses to increase as they progress towards clinical trials, with selective growth in headcount primarily in data science and biology [52][53] Question: What proportion of new data points is attributed to refining current programs versus looking at new candidates? - The majority of the new data points are focused on new categories, with significant enrichment in cancers where the company is already developing programs [57] Question: How has RADR helped refine the way the company looks at data and evolves curation? - Management noted improvements in data tagging and automation processes, which enhance the ability to analyze and utilize data effectively [59][61]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS ...

| --- | --- | --- | |------------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | Leveraging A.I., Machine Learning & Genomics to Rescue, Repurpose and | | | | Develop Targeted Cancer Therapies | | | SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS • This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Washington, D.C. 20549 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) ...